Project Grant R01CA304204
Award Date 9/19/25
Completion Date 8/31/29
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charlestown, MA 02129, USA
Similar Awards
- This Project Grant award of $231,413 from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) aims to develop a novel SPINEX (Separation-Processing Integration for Extracellular Vesicles) technology to streamline sample preparation for extracellular vesicle (EV) analysis. The project, awarded to The General Hospital Corporation (doing business as Massachusetts General Hospital), has two key objectives: Implement a fully automated, multi-functional SPINEX...
- This $516,355.74 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, aims to develop new technologies for immunotherapy monitoring and liquid biopsy through the Cancer Research Manpower federal grant program. Specifically, the Massachusetts General Hospital will utilize the funding to create an ultra-high sensitive platform that can map single extracellular vesicles to parent cells at the single particle level and apply it to profile tumor...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $1,221,128 to the University of Massachusetts Boston to investigate the biomechanical and biomolecular properties of large extracellular vesicles (L-EVs). The research aims to advance microfluidic technology to measure single L-EVs, characterize L-EV heterogeneity and subtypes associated with glioblastoma (GBM) mutations, and explore the clinical value of multiplex L-EV analysis from plasma...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $625,756 to The Trustees of the University of Pennsylvania to develop a high-throughput microfluidic platform for ultra-sensitive profiling of individual extracellular vesicles (EVs) in plasma. The platform, titled "Bead-Based Digital Single Molecule-Single EV Sorting (BDEVS)", aims to overcome limitations of current low-throughput imaging approaches by...
- The U.S. National Cancer Institute has awarded a $195,240 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a single-cell assay for correlating genome, transcriptome, and dynamic behaviors of metastatic cancer cells in an in vivo mice model. The project aims to employ laser particles that emit ultrabright narrowband laser emission to create unique optical barcodes for...
- This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training Program (CFDA 93.859), is focused on developing a novel high-throughput, high-content imaging platform for analyzing extracellular vesicles (EVs) at the single-particle level. The $298,999 award to Numentus Technologies Inc. will fund the construction, testing, and application of this platform to detect and characterize EV subpopulations, including...
- The National Cancer Institute (NCI), through the Cancer Detection and Diagnosis Research program (CFDA 93.394), awarded a $678,228 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop GLISCAN - a multi-analyte, multi-mutation blood-based assay for rapid, sensitive molecular subtyping of gliomas. The 5-year project aims to optimize, verify, and validate the GLISCAN assay, which will quantify tumor mutations (TERT C228T/C250T,...
- This Project Grant award, valued at $684,107 and funded by the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research), supports research to integrate circulating tumor cell and nuclear imaging biomarkers to assess the response and resistance to Lutetium-177-PSMA (LUPSMA) radiopharmaceutical therapy in advanced prostate cancer patients. The award was granted to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), a renowned...
- The Department of Health and Human Services' National Cancer Institute awarded a $644,034 Project Grant on March 11, 2025 under the Cancer Treatment Research (CFDA 93.395) program to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH). The grant is for the development of a "scintillating nanoparticle drug depot (SCIDD) platform" that uses nanoparticles to convert X-ray energy into light, which can then release potent and tumor-penetrating...
- The National Cancer Institute, under the Cancer Biology Research Federal Grant Program (CFDA 93.396), awarded a $680,594 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research on the novel regulation and functions of the TEAD-VGLL transcription factor complex. The key objectives of the 5-year project include: (1) characterizing the structure and functions of the TEAD-VGLL3 complex, (2) investigating TEAD-VGLL3's role in...